Banyu Launches Merck’s Isentress HIV Drug In Japan
This article was originally published in PharmAsia News
Executive Summary
Banyu Pharmaceutical launched in Japan the HIV treatment Isentress (raltegravir), the only drug of its kind for blocking the virus that causes AIDS. The drug works by inserting viral DNA into human DNA to inhibit the integrase enzyme. Banyu is a wholly owned subsidiary of U.S. drug maker Merck. The drug also can help HIV-infected people who have developed a resistance to other drugs. (Click here for more - a subscription may be required